Menu
Search
|

Menu

Close
X

Redhill Biopharma Ltd RDHL.OQ (NASDAQ Stock Exchange Capital Market)

6.22 USD
-0.04 (-0.64%)
As of 3:59 PM EST
chart
Previous Close 6.26
Open 6.25
Volume 36,465
3m Avg Volume 44,657
Today’s High 6.25
Today’s Low 6.01
52 Week High 11.24
52 Week Low 4.30
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
--
8.23
Price to Book (MRQ)
vs sector
--
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
--
15.44
LT Debt to Equity (MRQ)
vs sector
--
12.05
Return on Investment (TTM)
vs sector
--
13.63
Return on Equity (TTM)
vs sector
--
15.25

EXECUTIVE LEADERSHIP

Dror Ben-Asher
Chairman of the Board, Chief Executive Officer, Since 2011
Salary: $262,454.00
Bonus: --
Micha Ben Chorin
Chief Financial Officer, Since 2016
Salary: $162,642.00
Bonus: --
Gilead Raday
Chief Operating Officer, Since 2016
Salary: $218,087.00
Bonus: $40,000.00
Reza Fathi
Senior Vice President - Research & Development, Since 2010
Salary: $246,000.00
Bonus: --
Adi Frish
Senior Vice President - Business Development and Licensing, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Platinum building, 21 Ha'arba'a
TEL AVIV-YAFO     6473921

Phone: +9723.5413131

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

SPONSORED STORIES